Literature DB >> 21532600

Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screening.

Michael S Borofsky1, Danil V Makarov.   

Abstract

Entities:  

Year:  2011        PMID： 21532600      PMCID： PMC3739626          DOI： 10.1038/aja.2011.38

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  14 in total

1.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Authors:  Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

2.  Measuring the importance of PSA velocity.

Authors:  Rabiya S Tuma
Journal:  J Natl Cancer Inst       Date:  2011-03-10       Impact factor: 13.506

3.  Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.

Authors:  Leon Sun; Judd W Moul; James M Hotaling; Edward Rampersaud; Phillipp Dahm; Cary Robertson; Nicholas Fitzsimons; David Albala; Thomas J Polascik
Journal:  BJU Int       Date:  2007-01-19       Impact factor: 5.588

4.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Authors:  Andrew J Vickers; Cathee Till; Catherine M Tangen; Hans Lilja; Ian M Thompson
Journal:  J Natl Cancer Inst       Date:  2011-02-24       Impact factor: 13.506

5.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

Review 6.  Active surveillance for prostate cancer: trials and tribulations.

Authors:  Laurence Klotz
Journal:  World J Urol       Date:  2008-09-24       Impact factor: 4.226

7.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

8.  Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

Authors:  Pim J van Leeuwen; David Connolly; Anna Gavin; Monique J Roobol; Amanda Black; Chris H Bangma; Fritz H Schröder
Journal:  Eur J Cancer       Date:  2009-10-03       Impact factor: 9.162

9.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Authors:  H Gilbert Welch; Peter C Albertsen
Journal:  J Natl Cancer Inst       Date:  2009-08-31       Impact factor: 13.506

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
View more
  1 in total

1.  A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia.

Authors:  Yasukazu Nakanishi; Hitoshi Masuda; Satoru Kawakami; Mizuaki Sakura; Yasuhisa Fujii; Kazutaka Saito; Fumitaka Koga; Masaya Ito; Junji Yonese; Iwao Fukui; Kazunori Kihara
Journal:  Asian J Androl       Date:  2012-07-09       Impact factor: 3.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.